UK: Glyphosate: Science On Trial

Last Updated: 31 August 2018
Article by David Wynn

The world's most popular weed killer, Glyphosate, is being placed under the microscope by scientists, regulators and plaintiff lawyers. Despite four decades of widespread commercial and domestic use on the assumption it was safe, there has been recent increased worldwide concern about myriad potential health effects of exposure to the substance.

A test case in California, has hit the headlines globally this week. This case resulted in the jury finding Roundup was unsafe and was a substantial factor in causing the Plaintiff school groundskeeper's lymphoma. Awarding $39.25 million in compensatory damages and $250 million in punitive damages, the jury also found that Monsanto had failed to adequately warn consumers of the risks associated with its products and that the company acted with malice or oppression. Monsanto has vigorously protested the safety of its product and indicated it intends to appeal.

Scientific opinion concerning the dangers of this emerging risk is divided. Some claim that exposure is linked to everything from cancer to infertility; whilst others conclude the pesticide does not pose a threat. With some countries already banning the compound and the judgment in the US, prudent businesses and insurers must consider steps to understand and mitigate their risk now.

Glyphosate is the main chemical in the world's most widely used pesticide. It was first introduced by Monsanto under the brand name 'Roundup' in 1974. Worldwide glyphosate use has increased 15 times since 1996 when resistant crops began to be genetically engineered. In the US, more than 750 products contain it and in the UK, 5.4 million acres of farmland are treated with glyphosate annually.

The current controversy largely results from conflicting reports about the chemical's risks to the environment and effects on the human population, particularly in relation to the food chain. A number of recent articles and studies claim products from corn to cosmetics contain harmful levels of glyphosate.

Concern is also arising from research reports that indicate glyphosate causes a variety of health problems including Alzheimer's disease, kidney and liver diseases, and reproductive problems. Animal data studies have also reportedly raised the possibility of health effects associated with chronic, ultra-low doses related to accumulation of these compounds in the environment.

The substance potentially presents an occupational hazard for those involved in its manufacture or whose employment entails its use. In addition, it presents a potential risk to consumers of food products given the potential for the chemical to transfer into foodstuffs including cereals, honey and even beer. Environmental contamination is also an issue as the chemical could filter from the soil into water courses.

Opponents of these studies claim they fail to properly contextualise the relatively de minimis levels of glyphosate, which are often reportedly below safe levels imposed by regulators. Others note it is considered to be very safe toxicologically and environmentally, with some showing the active ingredient to be less acutely toxic to humans than table salt or aspirin. Research around this compound is also becoming increasingly politicised, with focus shifting to the resultant reduction in crop yields and the impact on international trade if a ban was to be implemented.

The debate intensified further in 2015 when the World Health Organization's International Agency for Research on Cancer categorised the chemical as a 'probable carcinogen'. The WHO concluded that exposure to glyphosate doubled a person's risk of developing non-Hodgkin's lymphoma (NHL). This new categorisation followed a number of previous studies that considered the link. One case-control study of occupational exposure in the US, Canada and Sweden reported increased risks for NHL. Another study showed a significant increase in the incidence of rare tumours, with a dose-related trend.

In marked contrast, the European Food Safety Authority (EFSA) claims that glyphosate is unlikely to be carcinogenic and is not dangerously toxic to humans. Indeed, some researchers have indicated a correlation between farming and lymphoma dating back to 1950s before glyphosate appeared on the market. However, many have placed doubts on the EFSA's findings as their assessment was conduct on a small number of studies which were predominantly provided by manufacturers, raising concerns as to inherent bias. In addition tests on mammals covered a short period (a maximum of 90 days) leaving questions concerning the effect of long-term exposure to these chemicals.

The regulatory position is no less clear, with countries including Canada and Australia imposing restrictions on public and private use of glyphosate. France also intends to impose a ban on glyphosate within the next three years. In contrast the EU has recently renewed the license for glyphosate use for another five years and last December the US Environmental Protection Agency released its draft health risk assessment concluding that glyphosate is not likely to be carcinogenic to humans. This evolving position should be watched with care, given such a confusing position brings inherent supply chain risks.

These developments are significant as they show that there is a significant split opinion between regulators, manufacturers and scientists on glyphosate's health effects. What is perhaps clear from this conflicting position is that further research is needed to consider the safe limits for glyphosate residues in water, food and animal feed taking all possible health risks into account before more valid conclusions can be reached.

The uncertainty has not deterred plaintiff lawyers, who are increasingly focusing on the potential link between glyphosate and cancer. The test case in California may be the tip of the iceberg as Monsanto's weed killer is at the centre of hundreds of other lawsuits heading toward trial in multidistrict litigation consolidated before a California federal court.

As in the test case, allegations of failing to adequately warn of the risks are likely to be central to future litigation. Similar allegations have been made against Johnson & Johnson in the ongoing asbestos talc litigation, which has resulted in a spate of high profile cases in which significant punitive damages were awarded by juries despite uncertainties in the scientific evidence.

Indeed if the findings of the WHO are accepted as conclusive, a dose related exposure that is deemed to double the risk of lymphoma would be likely to satisfy the UK's and other common law jurisdictions' evidential tests to render the loss compensable. Employers whose personnel use the chemical are most at risk of exposure to claims, although this has the potential to extend to consumers using the product and possibly even to cases of environmental exposure.

Employers and their insurers must be mindful of this developing regulatory and claims environment and will wish to consider steps to assess and mitigate their potential risks. Whilst the full nature of the threat is unlikely to be determined for some time, a cautious approach would be advised to prevent any unwanted side effects.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions